Metabolomic Signatures for Predicting, Diagnosing, and Prognosing Various Diseases Including Cancer
AssigneeMetabolomycs, Inc.
InventorsRobert Nagourney, Ismael Silva, Paulo D'Amora
Life of this patent
Estimating the term…
Abstract
A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.
Claims20
A method for assessing a human patient for pancreatic cancer, comprising:
- using a technology selected from chromatography, spectroscopy, and spectrometry to quantify a plurality of metabolites included in a blood sample obtained from said human patient, including at least Dodecanedioylcarnitine and Lysophosphatidylcholine;
- normalizing data values obtained in the quantification of at least said Dodecanedioylcarnitine and said Lysophosphatidylcholine;
- comparing at least a result of an equation comprising at least a first ratio of said Dodecanedioylcarnitine and said Lysophosphatidylcholine, as normalized, to at least one predetermined value to both diagnose said human patient for said pancreatic cancer and determine a prognosis for said human patient, said at least one predetermined value being a second result of said equation using normalized and quantified metabolites including at least Dodecanedioylcarnitine and Lysophosphatidylcholine from a second sample taken from a second human patient with at least a known diagnosis for pancreatic cancer;
- wherein said diagnosis for said human patient includes at least whether said human patient has pancreatic cancer and said prognosis for said human patient includes at least a risk factor associated with said pancreatic cancer, said risk factor being a score on a linear scale that indicates at least one of a survival rate for said human patient and a response to treatment for pancreatic cancer.
A system for assessing a human patient for pancreatic cancer, comprising:
- a computing system comprising at least one memory device for storing machine readable instructions configured to perform the steps of:
- receive a plurality of quantified metabolites from a sample provided by said human patient, including at least Dodecanedioylcarnitine and Lysophosphatidylcholine, said quantification being performed using a technology selected from one of chromatography, spectroscopy, and spectrometry;
- normalize said plurality of quantified metabolites;
- compare at least a result of an equation comprising at least a first ratio of said Dodecanedioylcarnitine and said Lysophosphatidylcholine, as normalized, to at least one predetermined value to determine at least one level of similarity therebetween, said at least one predetermined value being a second result of said equation using normalized and quantified metabolites from a second sample taken from a second human patient with at least a known diagnosis for pancreatic cancer;
- and
- use said at least one level of similarity to determine a diagnosis and a prognosis for said human patient regarding said pancreatic cancer;
- wherein said diagnosis includes at least whether said human patient has pancreatic cancer and said prognosis includes at least a risk factor for said human patient associated with said pancreatic cancer, said risk factor being a score on a scale that indicates at least one of a rate of survival for said human patient and a response to treatment for pancreatic cancer.
Dependencies are inferred from the claim text.